8-K

​

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

​

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

​

Date of report (Date of earliest event reported): June 27, 2024

​

HARMONY BIOSCIENCES HOLDINGS, INC .

(Exact name of registrant as specified in its charter)

​

​	​	​
Delaware	001-39450	82-2279923
(State or other jurisdiction	(Commission	(IRS Employer
of incorporation)	File Number)	Identification No.)

​

630 W. Germantown Pike , Suite 215

Plymouth Meeting , PA **** 19462

(Address of principal executive offices) (Zip Code)

( 484 ) 539-9800

(Registrant’s telephone number, including area code)

N/A

(Former name or former address, if changed since last report.)

​

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

​

☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

​

☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

​

☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

​

Securities registered pursuant to Section 12(b) of the Act:

​	​	​	​	​
​	****	Trading	****	Name of each exchange
Title of each class	​	Symbol(s)	​	on which registered
Common Stock, $0.00001 par value per share	​	HRMY	​	The Nasdaq Global Market

​

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

​

Emerging growth company ☐

​

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

​

​

​

​

Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

​

​

On June 27, 2024, Jack Bech Nielsen notified the Board of Directors (the “Board”) of Harmony Biosciences Holdings, Inc. (the “Company”) that he is resigning from the Board effective immediately, due to health reasons. Mr. Nielsen’s decision was not due to any disagreement with the Company or the Board on any matter relating to the operations, policies or practices of the Company. The Company thanks Mr. Nielsen for his commitment and service to the Company and wishes him all the best.

​

Item 8.01 Other Events.

​

On July 1, 2024, the Company announced the change of the name of its wholly owned subsidiary from “Zynerba Pharmaceuticals, Inc.” to “Harmony Biosciences Management, Inc.” As of July 1, 2024, Zynerba Pharmaceuticals, Inc. is now known as Harmony Biosciences Management, Inc.

​

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits.

​	​	​
Exhibit		​
No.	​	Description
​	​	​
104	​	Cover Page Interactive Data File (embedded within the Inline XBRL document).

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

​	​	​
​	HARMONY BIOSCIENCES HOLDINGS, INC.
​	​
Date: July 1, 2024	By:	/s/ Jeffrey M. Dayno
​	​	Jeffrey M. Dayno
​	​	President, Chief Executive Officer and Director

​

​

​